Wimmer, Bernadette
Mangesius, Stephanie
Seppi, Klaus
Iglseder, Sarah
Di Pauli, Franziska
Ortler, Martin
Gizewski, Elke
Poewe, Werner
Wenning, Gregor Karl
Article History
Received: 27 August 2019
Accepted: 28 February 2020
First Online: 12 March 2020
Ethics approval and consent to participate
: We obtained written informed consent from the patient. The authors confirm that the approval of an institutional ethical review committee was not required for this work. We confirm that we adhered to CARE guidelines/methodology.
: We obtained written informed consent for publication from the patient.
: The authors report no sources of funding and no conflicts of interest concerning the research related to the manuscript.Financial Disclosures of all authors for the preceding 12 months (not related to the manuscript).Bernadette Wimmer reports grants from the Austrian science fund (FWF) and the Austrian Parkinson’s Disease Society.Stephanie Mangesius reports a grant from the Austrian Parkinson’s Disease Society.Klaus Seppi reports grants from Oesterreichische Nationalbank (Austrian Central Bank, Anniversary Fund; project no.: 14174), FWF Austrian Science Fund (FWF: Der Wissenschaftsfonds; project no.: KLI82-B00), Michael J. Fox Foundation, International Parkinson and Movement Disorder Society and personal fees from International Parkinson and Movement Disorder Society, from Teva, Boehringer-Ingelheim, UCB, Lundbeck and AOP Orphan Pharmaceuticals AG, Roche and Abbvie outside the submitted work.Elke R. Gizewski reports personal fees from Bracco and Bayer.Werner Poewe reports personal fees from AbbVie, Allergan, AstraZeneca, BIAL, Biogen, Boehringer-Ingelheim, Boston Scientific, GlaxonSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Novaris, Orion Pharma, Teva, UCB and Zambon (consultancy and lecture fees in relation to clinical drug development programs for PD) and royalties from Thieme, Wiley Blackwell, Oxford University Press and Cambridge University press.Gregor Wenning reports consulting fees and lecture fees from Astra Zeneca and lecture fees from Abbvie.Martin Ortler has nothing to disclose.